Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9% – What’s Next?

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) fell 9% during mid-day trading on Thursday . The stock traded as low as $9.12 and last traded at $8.94. 161,265 shares changed hands during trading, an increase of 112% from the average session volume of 75,959 shares. The stock had previously closed at $9.83.

Wall Street Analysts Forecast Growth

Several research firms recently commented on KPTI. HC Wainwright upped their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday. Piper Sandler increased their price objective on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. StockNews.com downgraded shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $45.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $62.75.

Karyopharm Therapeutics Trading Down 15.1 %

The stock’s 50-day moving average is $0.84 and its 200-day moving average is $0.82. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -8.19 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Wednesday, February 19th. The company reported ($3.60) EPS for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The business had revenue of $30.54 million during the quarter, compared to analysts’ expectations of $30.29 million. On average, equities analysts predict that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of KPTI. Geode Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock worth $1,125,000 after acquiring an additional 43,856 shares in the last quarter. GSA Capital Partners LLP raised its holdings in Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after acquiring an additional 792,283 shares in the last quarter. FMR LLC grew its holdings in Karyopharm Therapeutics by 26.1% during the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock worth $307,000 after acquiring an additional 76,510 shares in the last quarter. Jane Street Group LLC increased its position in shares of Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock worth $506,000 after purchasing an additional 543,556 shares during the last quarter. Finally, Focus Partners Wealth acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at about $31,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).